Herzschrittmachertherapie & Elektrophysiologie

, Volume 18, Issue 4, pp 259–268 | Cite as

Endpunkte für Studien bei Patienten mit Vorhofflimmern

Bericht über ein Konsensus-Papier von AFNET und EHRA
  • Paulus Kirchhof
  • Andreas Goette
  • Gerd Hindricks
  • Stefan Hohnloser
  • Karl-Heinz Kuck
  • Thomas Meinertz
  • Ursula Ravens
  • Gerhard Steinbeck
  • Günter Breithardt
ÜBERSICHT
  • 48 Downloads

Outcome parameters for AF trials – executive summary of an AFNET-EHRA consensus conference

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the An Ticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Jama 285:2370–2375PubMedCrossRefGoogle Scholar
  2. 2.
    Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC (2006) Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27:949–953PubMedCrossRefGoogle Scholar
  3. 3.
    Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ (2004) Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110:1042–1046PubMedCrossRefGoogle Scholar
  4. 4.
    Stewart S, Hart CL, Hole DJ, McMurray JJ (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 113:359–364PubMedCrossRefGoogle Scholar
  5. 5.
    Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946–952PubMedGoogle Scholar
  6. 6.
    Jouven X, Desnos M, Guerot C, Ducimetiere P (1999) Idiopathic atrial fibrillation as a risk factor for mortality. The Paris Prospective Study I. Eur Heart J 20:896–899PubMedCrossRefGoogle Scholar
  7. 7.
    Vidaillet H, Granada JF, Chyou PH, Maassen K, Ortiz M, Pulido JN, Sharma P, Smith PN, Hayes J (2002) A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 113:365–370PubMedCrossRefGoogle Scholar
  8. 8.
    Chen YH, Xu SJ, Bendahhou S, Wang XL, Wang Y, Xu WY, Jin HW, Sun H, Su XY, Zhuang QN, Yang YQ, Li YB, Liu Y, Xu HJ, Li XF, Ma N, Mou CP, Chen Z, Barhanin J, Huang W (2003) KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299:251–254PubMedCrossRefGoogle Scholar
  9. 9.
    Kirchhof P, Eckardt L, Franz MR, MönnigG, Loh P,Wedekind H, Schulze-Bahr E, Breithardt G, Haverkamp W (2003) Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias inpatientswith longQT syndrome. J Cardiovasc Electrophysiol 14:1027–1033PubMedCrossRefGoogle Scholar
  10. 10.
    Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB (2005) Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45:712–719PubMedCrossRefGoogle Scholar
  11. 11.
    Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL (1994) Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 89:224–227PubMedGoogle Scholar
  12. 12.
    Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G (2004) Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25:1385–1394PubMedCrossRefGoogle Scholar
  13. 13.
    Hohnloser SH, Kuck KH, Lilienthal J (2000) Rhythm or rate control in atrial fibrillation –Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356:1789–1794PubMedCrossRefGoogle Scholar
  14. 14.
    Lip GY, Edwards SJ (2006) Stroke prevention with aspirin, warfarin and ximelagatran in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 118:321–333PubMedCrossRefGoogle Scholar
  15. 15.
    Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN (1999) Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover openlabel study of five drug regimens. J Am Coll Cardiol 33:304–310PubMedCrossRefGoogle Scholar
  16. 16.
    AFFIRM I (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833CrossRefGoogle Scholar
  17. 17.
    Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, LeMouroux A, LeMetayer P, Clementy J (1998) Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659–666PubMedCrossRefGoogle Scholar
  18. 18.
    Cox JL (2004) Cardiac surgery for arrhythmias. Pacing Clin Electrophysiol 27:266–282PubMedCrossRefGoogle Scholar
  19. 19.
    Healey JS, Morillo CA, Connolly SJ (2005) Role of the renin-angiotensinaldosterone system in atrial fibrillation and cardiac remodeling. Curr Opin Cardiol 20:31–37PubMedGoogle Scholar
  20. 20.
    Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G (2007) Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace (published on line Sept 25, 2007, http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed &dopt=Citation&list_uids=17897925)Google Scholar
  21. 21.
    Kirchhof P,Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B,Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G (2007) Outcome parameters for trials in atrial fibrillation: executive summary: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J (published on line Sept 25, 2007, http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids= 17897924)Google Scholar
  22. 22.
    Gillis AM, Rose MS (2000) Temporal patterns of paroxysmal atrial fibrillation following DDDR pacemaker implantation. Am J Cardiol 85:1445–1450PubMedCrossRefGoogle Scholar
  23. 23.
    Warman EN, Grammatico A, Padeletti L (2004) Sample size estimates for atrial fibrillation endpoints. Heart Rhythm 1:B58–62 (discussion B63)PubMedCrossRefGoogle Scholar
  24. 24.
    Pritchett EL, Anderson JL (1988) Antiarrhythmic strategies for the chronic management of supraventricular tachycardias. Am J Cardiol 62:1D–2DPubMedCrossRefGoogle Scholar
  25. 25.
    Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD Jr, Raisch DW, Ezekowitz MD (2005) Amiodarone vs sotalol for atrial fibrillation. N Engl J Med 352:1861–1872PubMedCrossRefGoogle Scholar
  26. 26.
    Berger M, Schweitzer P (1998) Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol 82:1545–1547, A8PubMedCrossRefGoogle Scholar
  27. 27.
    Gallagher MM, Hennessy BJ, EdvardssonN, Hart CM, Shannon MS, ObelOA, Al-SaadyNM,CammAJ (2002) Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 40:926–933PubMedCrossRefGoogle Scholar
  28. 28.
    Godtfredson J (1975) Atrial fibrillation, etiology, course and prognosis. A follow-up study of 1212 cases. University of Copenhagen, CopenhagenGoogle Scholar
  29. 29.
    Olsson SB (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691–1698PubMedCrossRefGoogle Scholar
  30. 30.
    McNamara RL, Brass LM, Drozda JP Jr, Go AS, Halperin JL, Kerr CR, Levy S, Malenka DJ, Mittal S, Pelosi F Jr, Rosenberg Y, Stryer D, Wyse DG, Radford MJ, Goff DC Jr, Grover FL, Heidenreich PA, Malenka DJ, Peterson ED, Redberg RF (2004) ACC/ AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation). Circulation 109:3223–3243PubMedCrossRefGoogle Scholar
  31. 31.
    Shemin RJ, Cox JL, Gillinov AM, Blackstone EH, Bridges CR (2007) Guidelines for reporting data and outcomes for the surgical treatment of atrial fibrillation. Ann Thorac Surg 83:1225–1230PubMedCrossRefGoogle Scholar
  32. 32.
    Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC (2001) Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 32:2559–2566PubMedCrossRefGoogle Scholar
  33. 33.
    Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS (1996) Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 27:1765–1769PubMedGoogle Scholar
  34. 34.
    Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348:1215–1222PubMedCrossRefGoogle Scholar
  35. 35.
    Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Full text: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8:651–745PubMedCrossRefGoogle Scholar
  36. 36.
    Albers GW (2004) Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. Am J Manag Care 10:S462–469; discussion S469–473PubMedGoogle Scholar
  37. 37.
    Diener HC (2006) Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 21:279–293PubMedCrossRefGoogle Scholar
  38. 38.
    Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke (1993) EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342:1255–1262Google Scholar
  39. 39.
    Akins PT, Feldman HA, Zoble RG, Newman D, Spitzer SG, Diener HC, Albers GW (2007) Secondary stroke prevention with ximelagatran vs warfarin in patients with atrial fibrillation. Pooled Analysis of SPORTIF III and V Clinical Trials. Stroke 2007Google Scholar
  40. 40.
    Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41PubMedGoogle Scholar
  41. 41.
    Rankin J (1957) Cerebral vascular accidents in patients over the age of 60, II: prognosis. Scot Med J 2:200–215Google Scholar
  42. 42.
    Thrall G, Lane D, Carroll D, Lip GY (2006) Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 119:448 e1–19PubMedCrossRefGoogle Scholar
  43. 43.
    Singh SN, Tang XC, Singh BN, Dorian P, Reda DJ, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD Jr, Lopez B, Raisch DW, Ezekowitz MD (2006) Quality of life and exercise performance in patients in sinus rhythm vs persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. J Am Coll Cardiol 48:721–730PubMedCrossRefGoogle Scholar
  44. 44.
    Dorian P, Paquette M, Newman D, Green M, Connolly SJ, Talajic M, Roy D (2002) Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J 143:984–990PubMedCrossRefGoogle Scholar
  45. 45.
    Testa L, Biondi-Zoccai GG, Dello Russo A, Bellocci F, Andreotti F, Crea F (2005) Rate-control vs rhythm-control in patients with atrial fibrillation: a metaanalysis. Eur Heart J 26:2000-2006PubMedCrossRefGoogle Scholar
  46. 46.
    Bloom JR, Stewart SL, Johnston M, Banks P (1998) Intrusiveness of illness and quality of life in young women with breast cancer. Psychooncology 7:89–100PubMedCrossRefGoogle Scholar
  47. 47.
    Devins GM (1994) Illness intrusiveness and the psychosocial impact of lifestyle disruptions in chronic lifethreatening disease. Adv Ren Replace Ther 1:251–263PubMedGoogle Scholar
  48. 48.
    Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH (2004) Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. JAmColl Cardiol 43:47–52CrossRefGoogle Scholar
  49. 49.
    Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, Dluzniewski M, Hatala R, Opolski G, Muller HW, Meinertz T (2004) Suppression of paroxysmal atrial tachyarrhythmias –results of the SOPAT trial. Eur Heart J 25:1395–1404PubMedCrossRefGoogle Scholar
  50. 50.
    Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C, Kottkamp H (2005) Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 112:307–313PubMedCrossRefGoogle Scholar
  51. 51.
    Piorkowski C, Kottkamp H, Tanner H, Kobza R, Nielsen JC, Arya A, Hindricks G (2005) Value of different follow- up strategies to assess the efficacy of circumferential pulmonary vein ablation for the curative treatment of atrial fibrillation. J Cardiovasc Electrophysiol 16:1286–1292PubMedCrossRefGoogle Scholar
  52. 52.
    de Voogt WG, van Hemel NM, van de Bos AA, Koistinen J, Fast JH (2006) Verification of pacemaker automatic mode switching for the detection of atrial fibrillation and atrial tachycardia with Holter recording. Europace 8:950–961PubMedCrossRefGoogle Scholar
  53. 53.
    Ziegler PD, Koehler JL, Mehra R (2006) Comparison of continuous vs intermittent monitoring of atrial arrhythmias. Heart Rhythm 3:1445–1452PubMedCrossRefGoogle Scholar
  54. 54.
    Kirchhof P, Fetsch T, Hanrath P, Meinertz T, Steinbeck G, Lehmacher W, Breithardt G (2005) Targeted pharmacological reversal of electrical remodeling after cardioversion –rationale and design of the Flecainide Short-Long (Flec-SL) trial. Am Heart J 150:899PubMedCrossRefGoogle Scholar
  55. 55.
    Lown B, Amarasinghem R, Neumann J (1962) New method for termination cardiac arrhythmias: use of synchronized capacitor discharge. JAMA 182:548–555PubMedGoogle Scholar
  56. 56.
    Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH, Böcker D, Breithardt G, Haverkamp W, Borggrefe M (2002) Anterior-posterior vs anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 360:1275–1279PubMedCrossRefGoogle Scholar
  57. 57.
    Mittal S, Ayati S, Stein KM, Schwartzman D, Cavlovich D, Tchou PJ, Markowitz SM, Slotwiner DJ, Scheiner MA, Lerman BB (2000) Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic vs damped sine wave monophasic shocks. Circulation 101:1282–1287PubMedGoogle Scholar
  58. 58.
    Marinsek M, Larkin GL, Zohar P, Bervar M, Pekolj-Bicanic M, Mocnik FS, Noc M, Podbregar M (2003) Efficacy and impact of monophasic vs biphasic countershocks for transthoracic cardioversion of persistent atrial fibrillation. Am J Cardiol 92:988–991PubMedCrossRefGoogle Scholar
  59. 59.
    Page RL, Kerber RE, Russell JK, Trouton T, Waktare J, Gallik D, Olgin JE, Ricard P, Dalzell GW, Reddy R, Lazzara R, Lee K, Carlson M, Halperin B, Bardy GH (2002) Biphasic vs monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol 39:1956–1963PubMedCrossRefGoogle Scholar
  60. 60.
    Ermis C, Zhu AX, Sinha S, Iskos D, Sakaguchi S, Lurie KG, Benditt DG (2002) Efficacy of biphasic waveform cardioversion for atrial fibrillation and atrial flutter compared with conventional monophasic waveforms. Am J Cardiol 90:891–892PubMedCrossRefGoogle Scholar
  61. 61.
    Kirchhof P, Mönnig G, Wasmer K, Heinecke A, Breithardt G, Eckardt L, Böcker D (2005) A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur H J 26:1292–1297CrossRefGoogle Scholar
  62. 62.
    Rossi M, Lown B (1967) The use of quinidine in cardioversion. Am J Cardiol 19:234–238PubMedCrossRefGoogle Scholar
  63. 63.
    Van Noord T, Van Gelder IC, Schoonderwoerd BA, Crijns HJ (2000) Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm and amiodarone. Am J Cardiol 86:1384–1385, A5PubMedCrossRefGoogle Scholar
  64. 64.
    Tieleman RG, Van Gelder IC, Crijns HJ, De Kam PJ, Van Den Berg MP, Haaksma J, Van Der Woude HJ, Allessie MA (1998) Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 31:167–173PubMedCrossRefGoogle Scholar
  65. 65.
    Brignole M, Gianfranchi L, Menozzi C, Bottoni N, Bollini R, Lolli G, Oddone D, Gaggioli G (1994) Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol 74:242–246PubMedCrossRefGoogle Scholar
  66. 66.
    Natale A, Zimerman L, Tomassoni G, Kearney M, Kent V, Brandon MJ, Newby K (1996) Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response. Am J Cardiol 78:1431–1433PubMedCrossRefGoogle Scholar
  67. 67.
    Rodriguez LM, Smeets JL, Xie B, de Chillou C, Cheriex E, Pieters F, Metzger J, den Dulk K, Wellens HJ (1993) Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 72:1137–1141PubMedCrossRefGoogle Scholar
  68. 68.
    Brignole M, Gianfranchi L, Menozzi C, Alboni P, Musso G, Bongiorni MG, Gasparini M, Raviele A, Lolli G, Paparella N, Acquarone S (1997) Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker vs pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation 96:2617–2624PubMedGoogle Scholar
  69. 69.
    Brignole M, Menozzi C, Gianfranchi L, Musso G, Mureddu R, Bottoni N, Lolli G (1998) Assessment of atrioventricular junction ablation and VVIR pacemaker vs pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation 98:953–960PubMedGoogle Scholar
  70. 70.
    Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D, Kanagaratnam L, Heddle W, Leitch J, Perks A, Ferguson L, Bulsara M (2003) The Australian intervention randomized control of rate in atrial fibrillation trial (AIRCRAFT). J Am Coll Cardiol 41:1697–1702PubMedCrossRefGoogle Scholar
  71. 71.
    Hsu LF, Jais P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquie JL, Scavee C, Bordachar P, Clementy J, Haissaguerre M (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351:2373–2383PubMedCrossRefGoogle Scholar
  72. 72.
    Hagens VE, Van Veldhuisen DJ, Kamp O, Rienstra M, Bosker HA, Veeger NJ, Tijssen JGP, Crijns HJ, Van Gelder I (2005) Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: Results from the RAte Control vs Electrical cardioversion for persistent atrial fibrillation (RACE) study. Heart Rhythm 2:19–24PubMedCrossRefGoogle Scholar
  73. 73.
    Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463PubMedCrossRefGoogle Scholar
  74. 74.
    Yamanaka K, Fujita M, Doi K, Tsuneyoshi H, Yamazato A, Ueno K, Zen E, Komeda M (2006) Multislice computed tomography accurately quantifies left atrial size and function after the MAZE procedure. Circulation 114:I5–9PubMedCrossRefGoogle Scholar
  75. 75.
    Abidov A, Hachamovitch R, Rozanski A, Hayes SW, Santos MM, Sciammarella MG, Cohen I, Gerlach J, Friedman JD, Germano G, Berman DS (2004) Prognostic implications of atrial fibrillation in patients undergoing myocardial perfusion singlephoton emission computed tomography. J Am Coll Cardiol 44:1062–1070PubMedCrossRefGoogle Scholar
  76. 76.
    Van Gelder I, Hagens VE, Bosker HA, Kingma H, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermanns AJM, Tijssen JGP, Crijns HJ (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834–1840PubMedCrossRefGoogle Scholar
  77. 77.
    Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P (2004) Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 126:476–486PubMedCrossRefGoogle Scholar
  78. 78.
    Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U, Investigators S (2003) Randomzied trial of rate-control vs rhythm-control in persistent atrial fibrillation. J Am Coll Cardiol 41:1690–1696PubMedCrossRefGoogle Scholar
  79. 79.
    Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagne P, Nattel S, Thibault B (2000) Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342:913–920PubMedCrossRefGoogle Scholar
  80. 80.
    Brignole M, Menozzi C, Gasparini M, Bongiorni MG, Botto GL, Ometto R, Alboni P, Bruna C, Vincenti A, Verlato R (2002) An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. Eur Heart J 23:892–900PubMedCrossRefGoogle Scholar
  81. 81.
    Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C (2002) Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106:331–336PubMedCrossRefGoogle Scholar
  82. 82.
    Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA (2003) Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 24:2090–2098PubMedCrossRefGoogle Scholar
  83. 83.
    Natale A, Newby KH, Pisano E, Leonelli F, Fanelli R, Potenza D, Beheiry S, Tomassoni G (2000) Prospective randomized comparison of antiarrhythmic therapy vs first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol 35:1898–1904PubMedCrossRefGoogle Scholar
  84. 84.
    Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, Bash D, Schweikert R, Brachmann J, Gunther J, Gutleben K, Pisano E, Potenza D, Fanelli R, Raviele A, Themistoclakis S, Rossillo A, Bonso A, Natale A (2005) Radiofrequency ablation vs antiarrhythmic drugs as firstline treatment of symptomatic atrial fibrillation: a randomized trial. Jama 293:2634–2640PubMedCrossRefGoogle Scholar
  85. 85.
    Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, Paglino G, Mazzone P, Sora N, Greiss I, Santagostino A, LiVolsi L, Pappone N, Radinovic A, Manguso F, Santinelli V (2006) A randomized trial of circumferential pulmonary vein ablation vs antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 48:2340–2347PubMedCrossRefGoogle Scholar
  86. 86.
    Oral H, Chugh A, Good E, Igic P, Elmouchi D, Tschopp DR, Reich SS, Bogun F, Pelosi F Jr, Morady F (2005) Randomized comparison of encircling and nonencircling left atrial ablation for chronic atrial fibrillation. Heart Rhythm 2:1165–1172PubMedCrossRefGoogle Scholar
  87. 87.
    Karch MR, Zrenner B, Deisenhofer I, Schreieck J, Ndrepepa G, Dong J, Lamprecht K, Barthel P, Luciani E, Schomig A, Schmitt C (2005) Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. Circulation 111:2875–2880PubMedCrossRefGoogle Scholar
  88. 88.
    Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr, Bates ER, Lehmann MH, Vicedomini G, Augello G, Agricola E, Sala S, Santinelli V, Morady F (2006) Circumferential pulmonary- vein ablation for chronic atrial fibrillation. N Engl J Med 354:934–941PubMedCrossRefGoogle Scholar
  89. 89.
    Gaita F, Riccardi R, Caponi D, Shah D, Garberoglio L, Vivalda L, Dulio A, Chiecchio A, Manasse E, Gallotti R (2005) Linear cryoablation of the left atrium vs pulmonary vein cryoisolation in patients with permanent atrial fibrillation and valvular heart disease: correlation of electroanatomic mapping and long-term clinical results. Circulation 111:136–142PubMedCrossRefGoogle Scholar
  90. 90.
    Roy D (2003) Rationale for the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Card Electrophysiol Rev 7:208–210PubMedCrossRefGoogle Scholar
  91. 91.
    Brignole M, Gammage M, Puggioni E, Alboni P, Raviele A, Sutton R, Vardas P, Bongiorni MG, Bergfeldt L, Menozzi C, Musso G (2005) Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation. Eur Heart J 26:712–722PubMedCrossRefGoogle Scholar
  92. 92.
    Van Gelder IC, Van Veldhuisen DJ, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Bosker HA, Cornel JH, Kamp O, Veeger NJ, Volbeda M, Rienstra M, Ranchor AV, TenVergert EM, Van den Berg MP (2006) Rate control efficacy in permanent atrial fibrillation: a comparison between lenient vs strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J 152:420–426PubMedCrossRefGoogle Scholar
  93. 93.
    Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B (1989) Placebo- controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1:175–179PubMedCrossRefGoogle Scholar
  94. 94.
    The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation (1990) The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 323:1505–1511CrossRefGoogle Scholar
  95. 95.
    Stroke Prevention in Atrial Fibrillation Study (1991) Final results. Circulation 84:527–539Google Scholar
  96. 96.
    Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ et al (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 327:1406–1412PubMedCrossRefGoogle Scholar
  97. 97.
    Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C (1991) Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 18:349–355PubMedCrossRefGoogle Scholar
  98. 98.
    Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, Boysen G (1998) Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 158:1513–1521PubMedCrossRefGoogle Scholar
  99. 99.
    Warfarin vs aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study (1994) Lancet 343:687–691Google Scholar
  100. 100.
    Adjusted-dose warfarin vs low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial (1996) Lancet 348:633–638CrossRefGoogle Scholar
  101. 101.
    Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. Jama 293:690–698PubMedCrossRefGoogle Scholar
  102. 102.
    Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A, Mataix L (2004) Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 44:1557–1566PubMedCrossRefGoogle Scholar
  103. 103.
    Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S (2006) Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:1903–1912PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2007

Authors and Affiliations

  • Paulus Kirchhof
    • 1
  • Andreas Goette
    • 2
  • Gerd Hindricks
    • 3
  • Stefan Hohnloser
    • 4
  • Karl-Heinz Kuck
    • 5
  • Thomas Meinertz
    • 6
  • Ursula Ravens
    • 7
  • Gerhard Steinbeck
    • 8
  • Günter Breithardt
    • 1
  1. 1.Medizinische Klinik und Poliklinik C, Kardiologie und AngiologieUniversitätsklinikum MünsterMünsterGermany
  2. 2.Medizinische Klinik I, KardiologieUniversität MagdeburgGermany
  3. 3.Herzzentrum LeipzigGermany
  4. 4.Medizinische Klinik II, KardiologieUniversitätsklinikum Frankfurt/MainGermany
  5. 5.Hanseatisches HerzzentrumAllgemeines Krankenhaus St. GeorgHamburgGermany
  6. 6.Medizinische Klinik (Kardiologie)Universitätsklinikum Hamburg-EppendorfGermany
  7. 7.Institut für Pharmakologie und ToxikologieTU DresdenGermany
  8. 8.Med. Klinik und Poliklinik ICampus Großhadern, LMUMünchenGermany

Personalised recommendations